Previous 10 | Next 10 |
home / stock / mdp:cc / mdp:cc news
TORONTO and CHICAGO, March 08, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (TSX: MDP; TSX: MDP.DB; OTCQX: MEDXF) today entered into a new senior secured credit agreement agented by BMO. The credit agreement provides for a US$35 million term loan facility and a US$3.5 ...
Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is a leader in innovative and rare disease treatment solutions with a strong North American commercial platform and a portfolio of proven best-in-class products. Their current focus is on the therapeutic areas of hematology, auto-immune diseases,...
TORONTO and CHICAGO, March 06, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (TSX: MDP; OTCQX: MEDXF) is pleased to announce that company management will be participating in the 35th Annual Roth Conference from March 12 to 14, 2023. Event : 35th Annual Roth Confer...
Results reflect growth across all leading prescription products, demonstrating continued track record of strong overall performance Management to host conference call at 8:00 AM Eastern Time on Thursday, February 9, 2023 TORONTO and CHICAGO, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Medexus...
Harmony P. Garges MD MPH and Menassie Taddese MBA appointed to Medexus’s board of directors Appointments bolster Medexus board’s medical and financial expertise, particularly in the United States TORONTO and CHICAGO, Feb. 06, 2023 (GLOBE NEWSWIRE) -...
TORONTO and CHICAGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals ( Medexus ) (TSX: MDP) (OTCQX: MEDXF) wishes to inform investors that the company has reached an agreement with the provincial government of Quebec for government-sponsored coverage of Cuvposa (glycopyrro...
TORONTO and CHICAGO, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals ( Medexus ) (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, February 9, 2023 to discuss Medexus’s results for its third fiscal quart...
TORONTO and CHICAGO, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals ( Medexus ) (TSX: MDP) (OTCQX: MEDXF) is pleased to announce preliminary estimates of the company’s revenue results for the fiscal quarter ended December 31, 2022 (the company’s fiscal ...
Results reflect strong growth across all leading prescription products, including IXINITY, Rupall, and Gleolan Management to host conference call at 8:00 AM Eastern Time on Wednesday, November 9, 2022 TORONTO and CHICAGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Medexus P...
TORONTO and CHICAGO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals ( Medexus ) (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Wednesday, November 9, 2022 to discuss Medexus’s results for its second quar...
News, Short Squeeze, Breakout and More Instantly...
Medexus Pharmaceuticals Inc. Company Name:
MDP:CC Stock Symbol:
TSXC Market:
Medexus Pharmaceuticals Inc. Website:
FDA has Accepted for Review the Treosulfan NDA Management to host conference call at 8:00 AM Eastern time on Wednesday, June 26, 2024 Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 25, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and...
Lomiko Metals Inc. (LMR:CA) is expected to report for Q3 2024 Organto Foods Inc. (OGO:CA) is expected to report for Q1 2024 PreveCeutical Medical Inc. (PREV:CNX) is expected to report for Q1 2024 Blue Horizon Global Capital Corp Com (BHCC:CNX) is expected to report for Q1 2024 Per...
Evertz Technologies Limited (ET:CA) is expected to report $0.22 for Q4 2024 Transat A.T. Inc. Voting and Variable Voting Shares (TRZ:CA) is expected to report $-0.66 for Q2 2024 Medexus Pharmaceuticals Inc. (MDP:CA) is expected to report $-0.03 for Q4 2024 FP Newspapers Inc. (FP:CA) i...